Sept 29 (Reuters) - Catabasis Pharmaceuticals Inc :
* Collaboration to study exon skipping treatment by Sarepta with co’s oral NF-KB inhibition treatment in mouse model of DMD
* Catabasis Pharmaceuticals and Sarepta Therapeutics announce a joint research collaboration in Duchenne muscular dystrophy
* Collaboration to explore a combination drug treatment approach for Duchenne muscular dystrophy Source text for Eikon: Further company coverage: ;))
Our Standards: The Thomson Reuters Trust Principles.